TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hospital-based Paraprofessional Lactation Clinic
Brief Summary: Hypothesis: We hypothesized that providing in-hospital, supervised paraprofessional breastfeeding consultation during the hiatus between hospital discharge and the first postpartum WIC or pediatric visit would increase the rate of exclusive breastfeeding among low income Hispanic women at 1 month postpartum.


Options:
A: Arm Label: Arm 1: BCC+PNS+CNS; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition-specific Behaviour change communication (BCC), Dietary Supplement: Nutrient supplement to pregnant women (PNS), Dietary Supplement: Nutrienr supplement to children 6m to 2 years | Arm Label: Arm 2: BCC+PNS; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition-specific Behaviour change communication (BCC), Dietary Supplement: Nutrient supplement to pregnant women (PNS) | Arm Label: Arm 3: BCC+CNS; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition-specific Behaviour change communication (BCC), Dietary Supplement: Nutrienr supplement to children 6m to 2 years | Arm Label: Arm 4: BCC only; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition-specific Behaviour change communication (BCC) | Arm Label: Arm 5: comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nutrition-specific Behaviour change communication (BCC); Assigned to Arm(s): Arm 1: BCC+PNS+CNS, Arm 2: BCC+PNS, Arm 3: BCC+CNS, Arm 4: BCC only | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutrient supplement to pregnant women (PNS); Assigned to Arm(s): Arm 1: BCC+PNS+CNS, Arm 2: BCC+PNS | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutrienr supplement to children 6m to 2 years; Assigned to Arm(s): Arm 1: BCC+PNS+CNS, Arm 3: BCC+CNS
B: Arm Label: Home-based counselling visits by volunteers; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based counselling | Arm Label: Standard care through existing health system; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home-based counselling; Assigned to Arm(s): Home-based counselling visits by volunteers
C: Arm Label: BFHI steps 1-9; Type: EXPERIMENTAL; Interventions: Other: implementation of the Baby-Friendly Hospital Initiative | Arm Label: BFHI steps 1-9 +well-child clinic; Type: EXPERIMENTAL; Interventions: Other: BFHI steps 1-9 +well-child clinic | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: implementation of the Baby-Friendly Hospital Initiative; Assigned to Arm(s): BFHI steps 1-9 | Intervention Type: OTHER; Name: BFHI steps 1-9 +well-child clinic; Assigned to Arm(s): BFHI steps 1-9 +well-child clinic
D: Intervention Type: BEHAVIORAL; Name: Proactive assignment to attend a breastfeeding clinic; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hospital-based Paraprofessional Lactation Clinic
Brief Summary: Hypothesis: We hypothesized that providing in-hospital, supervised paraprofessional breastfeeding consultation during the hiatus between hospital discharge and the first postpartum WIC or pediatric visit would increase the rate of exclusive breastfeeding among low income Hispanic women at 1 month postpartum.


Options:
A: Intervention Type: BEHAVIORAL; Name: Proactive assignment to attend a breastfeeding clinic; Assigned to Arm(s): N/A
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention
C: Intervention Type: BEHAVIORAL; Name: Improved management of severe neonatal infections; Assigned to Arm(s): N/A
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hospital-based Paraprofessional Lactation Clinic
Brief Summary: Hypothesis: We hypothesized that providing in-hospital, supervised paraprofessional breastfeeding consultation during the hiatus between hospital discharge and the first postpartum WIC or pediatric visit would increase the rate of exclusive breastfeeding among low income Hispanic women at 1 month postpartum.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention
B: Arm Label: Lactation Consultant; Type: ACTIVE_COMPARATOR; Interventions: Other: Lactation Consultant support | Arm Label: current treatment for jaundice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Lactation Consultant support; Assigned to Arm(s): Lactation Consultant
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Intensity; Type: OTHER; Interventions: Other: Telephone-based breastfeeding peer counseling | Arm Label: High Intensity; Type: ACTIVE_COMPARATOR; Interventions: Other: Telephone-based breastfeeding peer counseling | Intervention Type: OTHER; Name: Telephone-based breastfeeding peer counseling; Assigned to Arm(s): High Intensity, Low Intensity
D: Intervention Type: BEHAVIORAL; Name: Proactive assignment to attend a breastfeeding clinic; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Myocardial Regeneration Using Cardiac Stem Cells Harvested From Right Atrial Appendages in Patients With Ischemic Cardiomyopathy.
Brief Summary: The purpose of this study is to investigate the safety of intracoronary cardiac stem cells (CSCs) therapy in humans. Currently, there is no effective intervention to regenerate (regrow) dead heart muscle after a heart attack.

The central hypothesis is that CSCs infused into nonviable myocardial segments will regenerate infarcted myocardium by differentiating into cardiomyocytes and other cell types. According to our hypothesis, CSC infusion regenerates myocardium with consequent improvement in contractile function of the heart and general clinical status.


Options:
A: Arm Label: CLBS14: Low-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: CLBS14 (low-dose) | Arm Label: CLBS14: High-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: CLBS14 (high-dose) | Arm Label: Placebo injection; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo injection | Intervention Type: BIOLOGICAL; Name: CLBS14 (low-dose); Assigned to Arm(s): CLBS14: Low-Dose Group | Intervention Type: BIOLOGICAL; Name: CLBS14 (high-dose); Assigned to Arm(s): CLBS14: High-Dose Group | Intervention Type: BIOLOGICAL; Name: placebo injection; Assigned to Arm(s): Placebo injection
B: Intervention Type: DRUG; Name: intracoronary infusion of progenitor cells; Assigned to Arm(s): N/A
C: Arm Label: Treatment group; Type: EXPERIMENTAL; Interventions: Biological: Treatment group | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Treatment group; Assigned to Arm(s): Treatment group
D: Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Biological: Auto-CD34+ cells | Arm Label: Active Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo: Diluent used to suspend Auto-CD34+ cells | Arm Label: Unblinded Standard of Care (SOC) Arm; Type: OTHER; Interventions: Other: Standard of care | Intervention Type: BIOLOGICAL; Name: Auto-CD34+ cells; Assigned to Arm(s): Treatment Arm | Intervention Type: BIOLOGICAL; Name: Placebo: Diluent used to suspend Auto-CD34+ cells; Assigned to Arm(s): Active Control Arm | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Unblinded Standard of Care (SOC) Arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fondaparinux Compared With Heparin to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery
Brief Summary: (i) Main Research Question(s): What is the effect of fondaparinux on coronary graft patency, heart attack, stroke, and death in patients who have undergone coronary artery bypass grafting (CABG)? To reliably answer this question requires a large randomised trial. We propose a pilot study to demonstrate the feasibility of recruiting patients into this study and of performing CT angiograms to measure graft patency at 30 days.

(ii) Why is this research important? Coronary artery bypass surgery has made a very important contribution to improving the health and survival of patients with advanced coronary artery disease but still has many problems. One in 10 patients experiences a heart attack at the time of surgery, 1 in 20 experiences a heart attack, stroke, or death during hospitalization, and 1 in 4 patients has at least 1 blocked graft within 1 year of surgery. Fondaparinux, a relatively new anticoagulant drug, has been shown to significantly reduce cardiovascular events and death in patients who have suffered a recent heart attack. Compared to established anticoagulant therapies for acute myocardial infarction, fondaparinux has been shown to be more effective with similar or lower risks of bleeding.

Fondaparinux, unlike the most commonly used anticoagulants, does not cause Heparin Induced Thrombocytopenia (HIT), a rare condition with extremely high morbidity and mortality.

This drug has never been studied in CABG patients. Our pilot study will provide key information about feasibility that will help us to design and perform a large definitive study in the future.

(iii) What is being studied? We will be looking at blood flow in bypass grafts, heart attack, stroke, venous thromboembolism and death. For safety we will be looking at bleeding, transfusion, and need for further surgery because of bleeding. We will also perform laboratory tests for HIT antibodies as their levels are prognostic for the development of HIT and are also related to morbidity and mortality. The incidence of actual HIT cases will also be recorded.


Options:
A: Intervention Type: DRUG; Name: Warfarin vs ASA; Assigned to Arm(s): N/A
B: Arm Label: Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: Desirudin (Iprivask™); Type: EXPERIMENTAL; Interventions: Drug: Desirudin (Iprivask™) | Intervention Type: DRUG; Name: Desirudin (Iprivask™); Assigned to Arm(s): Desirudin (Iprivask™) | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Heparin
C: Arm Label: Antithrombin III treatment group; Type: EXPERIMENTAL; Interventions: Drug: Antithrombin III | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Antithrombin III; Assigned to Arm(s): Antithrombin III treatment group
D: Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Oscillation for ARDS Treated Early (OSCILLATE) Trial Pilot Study
Brief Summary: Acute respiratory distress syndrome (ARDS) is a common and catastrophic complication of critical illness related to burns, motor vehicle accidents, or overwhelming infection. ARDS kills 40-70% of affected patients. Patients with ARDS require life support in the form of a ventilator to breathe for them while their lungs heal. Ironically, ventilators can cause further damage to the lungs. We are conducting a study comparing 2 methods to protect the lungs from further damage. One method uses standard mechanical ventilators and the other uses a new type of ventilator, called a high frequency oscillator. We propose to test whether this high frequency oscillation will reduce the relative risk of dying from ARDS. 72 patients from 12 intensive care units in Canada and Saudi Arabia will participate in this preliminary study to test the feasibility of our study methods. If feasible, we plan to move on and conduct a large multinational study to definitively answer this question.


Options:
A: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: High-frequency Oscillation and Tracheal Gas Insufflation | Intervention Type: OTHER; Name: High-frequency Oscillation and Tracheal Gas Insufflation; Assigned to Arm(s): 1
B: Intervention Type: DEVICE; Name: High-frequency oscillation; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Conventional lung-open mechanical ventilation; Assigned to Arm(s): N/A
C: Arm Label: prone position; Type: ACTIVE_COMPARATOR; Interventions: Procedure: prone positioning | Arm Label: supine position; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: prone positioning; Assigned to Arm(s): prone position
D: Arm Label: HFO-TGI; Type: EXPERIMENTAL; Interventions: Other: High Frequency Oscillation and Tracheal Gas Insufflation | Arm Label: CMV; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: High Frequency Oscillation and Tracheal Gas Insufflation; Assigned to Arm(s): HFO-TGI

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Oscillation for ARDS Treated Early (OSCILLATE) Trial Pilot Study
Brief Summary: Acute respiratory distress syndrome (ARDS) is a common and catastrophic complication of critical illness related to burns, motor vehicle accidents, or overwhelming infection. ARDS kills 40-70% of affected patients. Patients with ARDS require life support in the form of a ventilator to breathe for them while their lungs heal. Ironically, ventilators can cause further damage to the lungs. We are conducting a study comparing 2 methods to protect the lungs from further damage. One method uses standard mechanical ventilators and the other uses a new type of ventilator, called a high frequency oscillator. We propose to test whether this high frequency oscillation will reduce the relative risk of dying from ARDS. 72 patients from 12 intensive care units in Canada and Saudi Arabia will participate in this preliminary study to test the feasibility of our study methods. If feasible, we plan to move on and conduct a large multinational study to definitively answer this question.


Options:
A: Arm Label: prone position; Type: ACTIVE_COMPARATOR; Interventions: Procedure: prone positioning | Arm Label: supine position; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: prone positioning; Assigned to Arm(s): prone position
B: N/A
C: Intervention Type: DEVICE; Name: High-frequency oscillation; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Conventional lung-open mechanical ventilation; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: prone position | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: prone position; Assigned to Arm(s): A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
Brief Summary: This is an international, randomized, open-label, outpatient, multicenter study. Subjects will be assigned in a 1:1 ratio to 1 of 2 treatment arms: temsirolimus 25 mg once weekly by intravenous (IV) infusion or sorafenib 400 mg by mouth (PO) twice daily (BID). These investigational drugs will be administered in 6-week cycles for the duration of the study, up to 24 months. Subjects will be stratified by nephrectomy status, duration of response to sunitinib therapy, Memorial Sloan Kettering Cancer Center (MSKCC) prognostic group, and RCC tumor histology.


Options:
A: Arm Label: Cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib tablets | Arm Label: Everolimus (Afinitor); Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus (Afinitor) tablets | Intervention Type: DRUG; Name: Cabozantinib tablets; Assigned to Arm(s): Cabozantinib (XL184) | Intervention Type: DRUG; Name: Everolimus (Afinitor) tablets; Assigned to Arm(s): Everolimus (Afinitor)
B: Arm Label: Arm 1: nivolumab - 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Arm Label: Arm 2: nivolumab - 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Arm Label: Arm 3: nivolumab - 10.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 1: nivolumab - 0.3 mg/kg | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 2: nivolumab - 2.0 mg/kg | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 3: nivolumab - 10.0 mg/kg
C: Arm Label: Atezolizumab + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Bevacizumab | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Assigned to Arm(s): Atezolizumab + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab + Bevacizumab | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: temsirolimus (Torisel) | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: temsirolimus (Torisel); Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Controlled Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema
Brief Summary: This trial is for men and women between the ages of 40 and 74 who have a confirmed diagnosis of emphysema. The objective of the trial is to determine the safety and effectiveness of the IBV Valve at redirecting airflow from diseased portions of the lung to healthier areas to achieve improvement in disease-related health status.


Options:
A: Arm Label: Chartis System-EBV Treatment; Type: OTHER; Interventions: Device: Chartis System, Device: Endobronchial Valve (EBV) Treatment | Intervention Type: DEVICE; Name: Chartis System; Assigned to Arm(s): Chartis System-EBV Treatment | Intervention Type: DEVICE; Name: Endobronchial Valve (EBV) Treatment; Assigned to Arm(s): Chartis System-EBV Treatment
B: Arm Label: BTVA; Type: EXPERIMENTAL; Interventions: Device: BTVA System | Intervention Type: DEVICE; Name: BTVA System; Assigned to Arm(s): BTVA
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: IBV® Valve System | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: IBV® Valve System | Intervention Type: DEVICE; Name: IBV® Valve System; Assigned to Arm(s): 1, 2
D: Intervention Type: PROCEDURE; Name: Emphasys Endobronchial Valve and procedure; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Low Molecular Weight Heparin on Survival of Stage I,II or IIIA Non Small Cell Lung Cancer. A Multicenter, Open, Randomized Controlled Trial.
Brief Summary: Experiments suggest that low molecular weight heparin (LMWH) inhibits tumor growth and metastasis. Studies in humans suggest that LMWH is associated with a higher survival in patients with cancer related thrombosis. Two recent studies suggest that LMWH may increase the survival of patients with cancer who do not have an associated thrombosis. The purpose of the study is to assess the effect of LMWH on the overall survival of patients with localized non-small cell lung cancer after complete surgical resection.


Options:
A: Arm Label: chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy at the investigator's discretion | Arm Label: dalteparin; Type: EXPERIMENTAL; Interventions: Drug: daltéparine, Drug: Chemotherapy at the investigator's discretion | Intervention Type: DRUG; Name: daltéparine; Assigned to Arm(s): dalteparin | Intervention Type: DRUG; Name: Chemotherapy at the investigator's discretion; Assigned to Arm(s): chemotherapy, dalteparin
B: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: diagnostic laboratory biomarker analysis; Assigned to Arm(s): N/A
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Intervention Type: DRUG; Name: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks; Assigned to Arm(s): A, B
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin, Drug: chemotherapy with LMWH - enoxaparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: only chemotherapy | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: chemotherapy with LMWH - enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: only chemotherapy; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Low Molecular Weight Heparin on Survival of Stage I,II or IIIA Non Small Cell Lung Cancer. A Multicenter, Open, Randomized Controlled Trial.
Brief Summary: Experiments suggest that low molecular weight heparin (LMWH) inhibits tumor growth and metastasis. Studies in humans suggest that LMWH is associated with a higher survival in patients with cancer related thrombosis. Two recent studies suggest that LMWH may increase the survival of patients with cancer who do not have an associated thrombosis. The purpose of the study is to assess the effect of LMWH on the overall survival of patients with localized non-small cell lung cancer after complete surgical resection.


Options:
A: Arm Label: Cohort A - Isoquercetin; Type: EXPERIMENTAL; Interventions: Drug: Isoquercetin | Arm Label: Cohort B - Isoquercetin; Type: EXPERIMENTAL; Interventions: Drug: Isoquercetin | Intervention Type: DRUG; Name: Isoquercetin; Assigned to Arm(s): Cohort A - Isoquercetin, Cohort B - Isoquercetin
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Intervention Type: DRUG; Name: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks; Assigned to Arm(s): A, B
C: Arm Label: Anticoagulants, aspirin; Type: N/A; Interventions: Drug: Heparin, fondaparinux, vitamin-K antagonists, aspirin | Intervention Type: DRUG; Name: Heparin, fondaparinux, vitamin-K antagonists, aspirin; Assigned to Arm(s): Anticoagulants, aspirin
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenalidomide, Drug: Prednisone, Drug: Melphalan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): A

Answer: B